Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) Net Margin (2018 - 2026)

10x Genomics' Net Margin history spans 8 years, with the latest figure at 9.79% for Q4 2025.

  • On a quarterly basis, Net Margin rose 1992.0% to 9.79% in Q4 2025 year-over-year; TTM through Dec 2025 was 6.77%, a 2313.0% increase, with the full-year FY2025 number at 6.77%, up 2313.0% from a year prior.
  • Net Margin hit 9.79% in Q4 2025 for 10x Genomics, up from 18.44% in the prior quarter.
  • Over the last five years, Net Margin for TXG hit a ceiling of 19.97% in Q2 2025 and a floor of 60.52% in Q3 2023.
  • Historically, Net Margin has averaged 25.09% across 5 years, with a median of 24.16% in 2024.
  • Biggest five-year swings in Net Margin: skyrocketed 35751bps in 2021 and later plummeted -4670bps in 2022.
  • Tracing TXG's Net Margin over 5 years: stood at 12.85% in 2021, then grew by 14bps to 11.02% in 2022, then tumbled by -141bps to 26.61% in 2023, then fell by -12bps to 29.71% in 2024, then skyrocketed by 67bps to 9.79% in 2025.
  • Business Quant data shows Net Margin for TXG at 9.79% in Q4 2025, 18.44% in Q3 2025, and 19.97% in Q2 2025.